Health Care • Biotechnology: Commercial Physical & Biological Resarch
$23.49 ▲ +0.02
(+0.09%)
MKT CAP: $519.6M • VOL: 125.0K
52W L $12 52W H $24
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$20
MEDIAN
$26
MEAN
$27
HIGH
$32
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE NRC TAPE
NRC // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $28.42 | $27.01 | 2025-02-14 | $21.38 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $29.60 | $27.72 | 2025-02-06 | $22.08 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $26.78 | $25.84 | 2025-01-29 | $22.55 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $23.96 | — | 2025-01-17 | $23.02 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $20.67 | $22.32 | 2025-01-09 | $20.91 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $27.95 | $24.43 | 2024-12-18 | $20.44 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $22.79 | $23.72 | 2024-12-04 | $21.85 | -4.3% | 48% | C |